Cell and Gene Therapy Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region|Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc.

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Cell and Gene Therapy Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The cell & gene therapy market size has grown exponentially in recent years. It will grow from $13.81 billion in 2023 to $17.31 billion in 2024 at a compound annual growth rate (CAGR) of 25.3%. The growth in the historic period can be attributed to increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and rising in pharmaceutical r&d expenditure.

The cell & gene therapy market size is expected to see exponential growth in the next few years. It will grow to $39.74 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure . Major trends in the forecast period include focusing on advanced therapies such as chimeric antigen receptor (car) t-cell therapy, concentrating on undertaking various research initiatives and attain funding, carrying out strategic collaborations to integrate advanced technologies, concentrating on developing gene/genome editing tools especially crispr, partnering or acquiring competitor companies, increasing the number of pipeline studies to develop cell and gene therapies, and investing in manufacturing facilities expansion.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

Market Segmentation:
The cell and gene therapy market covered in this report is segmented -

1) By Product: Cell Therapy, Gene Therapy
2) By Application: Oncology, Neurological Disorders, Other Applications
3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Major Driver - Strategic Investments And Industry Consolidation Drive Growth In The Cell And Gene Therapy Market
Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market. After recognizing the potential of the CGT market, 16 out of the 20 largest biopharmaceutical companies by revenue, added CGT products to their portfolios. For instance, in December 2021, Pfizer has invested $68.5 million in a new state-of-the-art facility in Durham, North Carolina, to further advance gene therapy capabilities. The facility expands Pfizer's end-to-end capabilities in gene therapy and builds on the company's existing footprint in North Carolina, which includes more than 3,600 employees across sites in the state. Steady investment and consolidation in CGT production capacity led to an increase in production capacity and also contributed to the growth of the market.

Competitive Landscape:
Major companies operating in the cell and gene therapy market report are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, and AstraZeneca.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Top Trend - Car T-Cell Therapy's Impact On The Cell And Gene Therapy Market
Chimeric antigen receptor (CAR) T-cell therapy is shaping the cell and gene therapy (CGT) market. (CAR) T-cell therapy is a combination of cell and gene therapy in which T cells are collected from the patient's blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors (CARs). These modified T cells have special structures (receptors) and are reinfused into the patient. Then, the modified receptors of T cells help in targeting the surface antigen of the cancer cell, ultimately resulting in the killing of tumor cells in patients. For instance, in June 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received approval from the United States Food and Drug Administration (US FDA) for CAR T cell therapy Breyanzi for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi is a differentiated CAR T cell therapy made from a patient's own T cells, which are collected and genetically reengineered to become CAR T cells that are then delivered via infusion as a one-time treatment.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Cell and Gene Therapy Market Characteristics
3. Cell and Gene Therapy Market Trends And Strategies
4. Cell and Gene Therapy Market - Macro Economic Scenario
5. Cell and Gene Therapy Market Size And Growth
…..
27. Cell and Gene Therapy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.